Tempest Therapeutics, Inc. · NASDAQ:TPST
Tempest Therapeutics — Investor Presentation (February 2026)
40 slides from Tempest Therapeutics's investor presentation, Feb 11, 2026
Slide 1: Accelerating the Development of Advanced Therapies for Cancer Patients
Exhibit 99.1 ® Accelerating the Development of Advanced Therapies for Cancer Patients February 2026
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) concerning Tempest Therapeutics, Inc. (“T
Slide 3: Partner-Funded Development Driving Diversified Oncology Pipeline with Capital Discipline
Partner-Funded Development Driving Diversified Oncology Pipeline with Capital Discipline Enables de-risked, data-driven deployment of internal capital 1 DEVELOPMENT STAGE Advanced By: IND- Indication(s) Discovery Preclinical Phase 1 Phase 2 Phase 3 Enabling Potential BD Amezalpat 1L HCC Partner PPAR
Slide 4: Selected Potential Value-Inflecting Milestones through Q4 27
Selected Potential Value-Inflecting Milestones through Q4 2027 2026 2027 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Phase 2b IIT and Phase 1 (China Tech transfer Phase 2b (U.S. Phase 2b TPST-2003 (China) results registrational) Phase 2b (U.S. complete registrational) (China File BLA CD19/BCMA Dual CAR-T enrollment reg
Slide 5: Dual Targeting CD19/BCMA CAR-T
TPST-2003 Dual Targeting CD19/BCMA CAR-T 5
Slide 6: TPST-2003 CD19/BCMA CAR-T
1 TPST-2003 CD19/BCMA CAR-T TPST-2003 is the world’s first parallel-structure dual-target CAR-T cell therapy focused on rrMM with EMD • rrMM (with extramedullary disease) (N=15): PET ORR 86.7% (13/15) Best in class Dual-target CAR-T structure • The incidence of ≥ grade 3 CRS was 4.3%, and the incide
Slide 7: Dual CAR-T for rrMM: CD19/BCMA Dual Targeting
TPST-2003 Dual CAR-T for rrMM: CD19/BCMA Dual Targeting 1 Jiang, H., et. al. “A Prospective Investigator-Initiated Phase 1/2 Study of BCMA/CD19 Dual-Targeting CAR T Therapy in Patients with Relapsed/Refractory 7 Multiple Myeloma Including Those with Extramedullary Disease”. Blood 144 (2024) 923-924.
Slide 8: Dual CAR-T for rrMM: IIT Study Design
TPST-2003 Dual CAR-T for rrMM: IIT Study Design 1 Jiang, H., et. al. “A Prospective Investigator-Initiated Phase 1/2 Study of BCMA/CD19 Dual-Targeting CAR T Therapy in Patients with Relapsed/Refractory 8 Multiple Myeloma Including Those with Extramedullary Disease”. Blood 144 (2024) 923-924.
Slide 9: Dual CAR-T for rrMM: Baseline Characteristics
TPST-2003 Dual CAR-T for rrMM: Baseline Characteristics 1 Jiang, H., et. al. “A Prospective Investigator-Initiated Phase 1/2 Study of BCMA/CD19 Dual-Targeting CAR T Therapy in Patients with Relapsed/Refractory 9 Multiple Myeloma Including Those with Extramedullary Disease”. Blood 144 (2024) 923-924.
Slide 10: Dual CAR-T for rrMM: Hematological Response
TPST-2003 Dual CAR-T for rrMM: Hematological Response 1 Jiang, H., et. al. “A Prospective Investigator-Initiated Phase 1/2 Study of BCMA/CD19 Dual-Targeting CAR T Therapy in Patients with Relapsed/Refractory Multiple Myeloma Including Those with Extramedullary Disease”. Blood 144 (2024) 923-924. 10
Slide 11: Dual CAR-T for rrMM: EMD Patient Baseline Characteristics
TPST-2003 Dual CAR-T for rrMM: EMD Patient Baseline Characteristics 1 Jiang, H., et. al. “A Prospective Investigator-Initiated Phase 1/2 Study of BCMA/CD19 Dual-Targeting CAR T Therapy in Patients with Relapsed/Refractory 11 Multiple Myeloma Including Those with Extramedullary Disease”. Blood 144 (2
Slide 12: Dual CAR-T for rrMM: EMD PET Response
TPST-2003 Dual CAR-T for rrMM: EMD PET Response 1 Jiang, H., et. al. “A Prospective Investigator-Initiated Phase 1/2 Study of BCMA/CD19 Dual-Targeting CAR T Therapy in Patients with Relapsed/Refractory 12 Multiple Myeloma Including Those with Extramedullary Disease”. Blood 144 (2024) 923-924.
Slide 13: Dual CAR-T for rrMM: EMD PET Response
TPST-2003 Dual CAR-T for rrMM: EMD PET Response 1 Jiang, H., et. al. “A Prospective Investigator-Initiated Phase 1/2 Study of BCMA/CD19 Dual-Targeting CAR T Therapy in Patients with Relapsed/Refractory 13 Multiple Myeloma Including Those with Extramedullary Disease”. Blood 144 (2024) 923-924.
Slide 14: Dual CAR-T for rrMM: Survival
TPST-2003 Dual CAR-T for rrMM: Survival 1 Jiang, H., et. al. “A Prospective Investigator-Initiated Phase 1/2 Study of BCMA/CD19 Dual-Targeting CAR T Therapy in Patients with Relapsed/Refractory 14 Multiple Myeloma Including Those with Extramedullary Disease”. Blood 144 (2024) 923-924.
Slide 15: Dual CAR-T for rrMM: Safety Profile
TPST-2003 Dual CAR-T for rrMM: Safety Profile 1 Jiang, H., et. al. “A Prospective Investigator-Initiated Phase 1/2 Study of BCMA/CD19 Dual-Targeting CAR T Therapy in Patients with Relapsed/Refractory 15 Multiple Myeloma Including Those with Extramedullary Disease”. Blood 144 (2024) 923-924.
Slide 16: Dual CAR-T for rrMM: Expansion and Persistence
TPST-2003 Dual CAR-T for rrMM: Expansion and Persistence 1 Jiang, H., et. al. “A Prospective Investigator-Initiated Phase 1/2 Study of BCMA/CD19 Dual-Targeting CAR T Therapy in Patients with Relapsed/Refractory 16 Multiple Myeloma Including Those with Extramedullary Disease”. Blood 144 (2024) 923-92
Slide 17: Dual CAR-T for rrMM: Conclusions
TPST-2003 Dual CAR-T for rrMM: Conclusions TPST-2003 is the world’s first parallel-structure dual-target CAR-T cell therapy focused on rrMM with EMD • TPST-2003 showed early, deep and durable response in Relapsed/Refractory MM patients − Hematological response (n=18): 100% ORR, 88.9% sCR/CR − MRD (n
Slide 18: Shows Similar Favorable Safety Profile to Approved BCMA CAR-T
TPST-2003 Shows Similar Favorable Safety Profile to Approved BCMA CAR-T Abecma Carvykti 1 TPST-2003 2 3 (BMS) (J&J/Legend) Target CD19, BCMA BCMA BCMA Stage IIT Approval Approval Indication rrMM rrMM rrMM 6 6 6 6 6 Target Dose 1x10 cells/kg 2x10 cells/kg 3x10 cells/kg 420x10 cells 0.75x10 cells/kg C
Slide 19: Performance Relative to Approved Therapies
TPST-2003 Performance Relative to Approved Therapies 1 TPST-2003 Abecma Carvykti 2 3 (BMS) (J&J/Legend) Target CD19, BCMA BCMA BCMA Stage Phase 1/2a Approval Approval Indication rrMM rrMM rrMM KarMMa CARTITUDE-1 Trial IIT (NCT 03361748) (NCT 03548207) Number of 15 50 19 EMD patients Median PFS of EM
Slide 20: Positive Performance Relative to GC012F (Gracell)
TPST-2003 Positive Performance Relative to GC012F (Gracell) GC012F 1 TPST-2003 2 (Gracell/AZ) Target CD19, BCMA CD19, BCMA Stage Phase 1/2a Phase 1b/2 Indication rrMM rrMM Median number of 5 5 previous treatments High-risk cytogenetics 66.7% -- Extramedullary disease 62.5% 27.6% ORR 100% 93.1% sCR/C
Slide 21: Amezalpat (TPST-1120) First-in-Class PPARα Antagonist
Amezalpat (TPST-1120) First-in-Class PPAR���� Antagonist 21
Slide 22: Amezalpat's Activity is Consistent from the Lab to the Clinic
Amezalpat’s Activity is Consistent from the Lab to the Clinic Amezalpat Pre-Clinical MOA Predicts Clinical Story Amezalpat Pre-Clinical Hypothesis: • FAO supports tumor cells, selective immune cells (suppressor, not effector), and angiogenesis • Blocking PPARα should provide an opportunity to benefi
Slide 23: Amezalpat (TPST-1120) in HCC: MOA Supports Indication & Combination Therapy
Amezalpat (TPST-1120) in HCC: MOA Supports Indication & Combination Therapy Amezalpat Pre-Clinical Hypothesis: FAO supports tumor cells, selective immune cells (suppressor, not effector), and angiogenesis 1 First-in-Class status is dependent on FDA approval 23 “FAO” = fatty-acid oxidation, “VEGF” =
Slide 24: Preclinical HCC Data Support Clinical Development Strategy
Preclinical HCC Data Support Clinical Development Strategy β-catenin pathway frequently activated in HCC: Potential Biomarker • Wnt/β-catenin pathway is critical for stem Efficacy in syngeneic β-Catenin-driven cell regeneration, and tumorigenesis (i.e., hepatocellular carcinoma model* EMT) • Activat
Slide 25: Amezalpat in Front-Line Phase 1b/2 HCC Randomized Study
Amezalpat (TPST-1120) in Front-Line Phase 1b/2 HCC Randomized Study Positive Global Randomized Phase 2 result positions Tempest for pivotal study HCC: Highest Expression of PPARα and FAO Genes • SoC 1L regimen +/- TPST-1120 • Ongoing multi-arm global 1 randomized study − US, Asia, Europe − 26 sites
Slide 26: Balanced Demographics and Baseline Characteristics
Balanced Demographics and Baseline Characteristics No statistically significant differences, although multiple numerical differences favor the SoC control arm TPST-1120 + Atezo+Bev (c) Demographic Result Atezo+Bev (N=30) (N=40) Age group (yr) >=65 12 (40.0%) 25 (62.5%) Sex Male 26 (86.7%) 33 (82.5%)
Slide 27: Amezalpat Arm Improves All Efficacy Endpoints vs. SoC Control
Amezalpat (TPST-1120) Arm Improves All Efficacy Endpoints vs. SoC Control Primary Global Regulatory atezo/bev TPST-1120 + atezo/bev Endpoint N=30 N=40 OS HR 0.65 15m 21m Consistent PFS HR 0.8 Median 4.27m (2.8, 7.3) 7m (5.6, 13.8) Improvement Across Confirmed ORR (ITT population) 13.3% 30% All PD-L1
Slide 28: Superior OS in Amezalpat Arm vs. Atezo-Bev Control
Superior OS in Amezalpat (TPST-1120) Arm vs. Atezo-Bev Control • HR 0.65 - early and persistent separation of survival curves 1 • Six-month improvement in mOS with 50% of amezalpat arm patients still in survival follow-up 1.00 A Closer Look at HR • Stable HR compared to April 2023 data cut (ten mont
Slide 29: AB SoC Control Arm Responses Enriched for PD-L1+ and Hot Tumors
AB SoC Control Arm Responses Enriched for PD-L1+ and Hot Tumors Atezo + Bev biomarker associations PD-L1 Score Immune Phenotype Primary data cut, per protocol - April 20, 2023 29
Slide 30: Amezalpat Responses Across the Board: Cold, Hot and β-catenin Tumors
mut & wt Amezalpat Responses Across the Board: Cold, Hot and β-catenin Tumors wt RECIST Complete Response in a PD-L1 negative, immune excluded and β-catenin (CTNNB1 ) tumor 100 Confirmed Best Overall Response Partial Response Stable Disease Progressive Disease Not Evaluable 50 (0) 0 -50 -100 PD-L1 S
Slide 31: Overall Survival Benefit Maintained Across Key Subpopulations
Overall Survival Benefit Maintained Across Key Subpopulations PATIENTS AMEZ-AB (%) vs AB (%) HR FOR DEATH (95% CI) PD-L1 Status Pos (≥1%) 13 (32.5%) vs 10 (34%) 0.36 (0.12-1.11) Neg (<1%) 26 (65%) vs 15 (52%) 0.64 (0.28-1.45) ECOG ECOG 0 26 (65%) vs 21 (72%) 0.63 (0.29-1.35) ECOG 1 14 (35%) vs 8 (28
Slide 32: Manageable Safety Profile Consistent with MOA and Phase Data
Manageable Safety Profile Consistent with MOA and Phase 1 Data Amezalpat combination’s safety profile is similar to AB SoC control arm Atezo + Bev Amez + Atezo + Bev Patients with Event, n (%) (N=29) (n=40) Grade 1 or 2 Severity TEAE 7 (24.1) 12 (30.0) Grade ≥ 3 TEAE 22 (75.9) 28 (70) Treatment-Rela
Slide 33: Pivotal Phase Study Design – FDA, EMA and NMPA Agreement
Pivotal Phase 3 Study Design – FDA, EMA and NMPA Agreement • Replicates positive Phase 2 study with additional size & power – increases probability of repeating Phase 2 result with regulatory statistical significance • Planned analyses that could shorten timeline; Phase 2 data are stronger than requ
Slide 34: Broadly Positive Regulatory Interactions for Amezalpat Pivotal Study
Broadly Positive Regulatory Interactions for Amezalpat Pivotal Study • FDA − Achieved FDA agreement on proposed amezalpat Phase 3 dose and schedule, including no Project Optimus requirement − FDA IND successful for final protocol and Study May Proceed − FDA Orphan Drug Designation granted December 2
Slide 35: First-Line HCC is a Large and Uncrowded Market
First-Line HCC is a Large and Uncrowded Market 1 Amezalpat’s MoA and lead position offers a unique opportunity to build a valuable program HCC Incidence Treated • 1L HCC is already large and expected to (BCLC B/C) grow 55% to 1.4M patients globally by US 32,128 14,233 2 2040 EU5 33,995 15,499 • Uncr
Slide 36: Amezalpat Combination is Poised for Phase 3 Global Registrational Trial
Amezalpat Combination is Poised for Phase 3 Global Registrational Trial Survival benefit over SOC in full patient population and key subgroups, with similar safety profile to SoC alone Stable 0.65 hazard ratio for OS – slight shift from 0.59 at topline through follow-up analysis ü Six-month improvem
Slide 37: TPST-1495 First-in-Class Dual EP2/4 Antagonist
TPST-1495 First-in-Class Dual EP2/4 Antagonist 37
Slide 38: TPST-1495 is a First-in-Class Dual EP2/EP4 PGE2 Receptor Antagonist
1 TPST-1495 is a First-in-Class Dual EP2/EP4 PGE2 Receptor Antagonist Rationally designed, based on an understanding of PGE2 signaling in cancer progression PGE2 Signaling Pathway 5-LOX • Prostaglandin E (PGE2) has both tumor 2 * Leukotrienes Arachidonic acid * promoting and tumor suppressing activi
Slide 39: TPST-1495 Program Summary: Moving Forward in FAP
TPST-1495 Program Summary: Moving Forward in FAP Phase 2 Familial Adenomatous Polyposis TPST-1495 therapy conferred a significant survival advantage (FAP) Program compared to other prostaglandin pathway inhibitors Min/+ • Therapeutic activity comparison in Apc mouse model of FAP • No approved therap
Slide 40: Accelerating the Development of Advanced Therapies for Cancer Patients
® Accelerating the Development of Advanced Therapies for Cancer Patients February 2026
Tempest Therapeutics — Investor Presentation (February 2026) on 6ix